Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: October 31, 2023
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: May 24, 2023
Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: March 27, 2023
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
Journal: Therapeutic advances in neurological disorders
Published: June 17, 2020
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
Journal: Journal of neurology
Published: December 12, 2019
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 16, 2017
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 10, 2017
iPS-derived neural progenitor cells from PPMS patients reveal defect in myelin injury response.
Journal: Experimental neurology
Published: July 01, 2016
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Journal: Advances in therapy
Published: March 30, 2016
Current and emerging therapies in multiple sclerosis: a systematic review.
Journal: Therapeutic advances in neurological disorders
Published: July 12, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026